Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Aavantgarde Bio s.r.l.
BioCentury | Oct 22, 2024
Management Tracks
Ray Jupp named CSO at ViaNautis
Plus: Pellegrini joins Kaia and an update from AAVantgarde
BioCentury | Sep 26, 2024
Finance
Eyes on Europe: Asabys’ €180M fund, Genespire’s record series B
BioCentury’s weekly Venture Report also includes Arch’s latest fund, Flagship-backed Mirai, series Bs for Vicebio and 858, and more
BioCentury | Sep 10, 2024
Management Tracks
Lucas Montarce named Lilly CFO
Plus: Yong Ben hired as chief medical and development officer of TheRas, and updates from Orbital, Latigo, AAVantgarde and more
BioCentury | Jun 6, 2023
Deals
June 6 Quick Takes: Alkermes wins arbitration with J&J
Plus: Gurnet Point, Novo taking Paratek private, and updates from Illumina, Sequoia, AAVantgarde, Acepodia and GSK
BioCentury | Sep 9, 2022
Management Tracks
Misciattelli becomes CEO of Aavantgarde
Plus new CMO, SVP of clinical development at Alumis, and updates from Vertex, Third Rock, AiCuris and more
BioCentury | May 13, 2022
Finance
In latest Italy deal, Sofinnova seeds nanodelivery start-up NanoPhoria with €3.5M
Targeted, non-viral drug delivery start-up is eighth deal for European firm’s Italy-focused Telethon Fund
BioCentury | May 13, 2022
Data Byte
Distillery spotlight on Italian innovation
Opportunities include compounds and targets for cancer, neurology and musculoskeletal diseases, and discoveries from company founders
BioCentury | Apr 29, 2022
Finance
Two years into Telethon Fund, Sofinnova builds Italy portfolio as ecosystem matures
European firm’s Seghezzi: Momentum building for scientific deal flow as region draws funding, teams, infrastructure
Items per page:
1 - 8 of 8